No description available.

No description available.

No description available.

No description available.

Monoclonal antibodies which recognise tumour-associated antigens provide a means of targeting radionuclides selectively to tumour cells. (^99m)Tc and (^64)Cu are potentially useful isotopes for radioimmunoimaging;(^ 90)Y and (^67)Cu may be suitable for radioimmunotherapy. The synthesis of functionalised macrocycles for binding these four radioisotopes to antibodies is described. In each case, a macrocycle has been selected to provide a complex which is kinetically inert, thereby preventing dissociation of the radiolabel in vivo. A novel strategy for conjugating a C-alkylated cyclam derivative (for binding Tc and Cu) to an antibody is described. This method facilitates the selective acylation of an exocyclic primary amino group in the presence of the secondary ring nitrogens. Unfortunately, the labelling of antibody-bound cyclam with (^99m)Tc required conditions (pH 11) which produced extensive binding of the radiolabel to the protein backbone. "Non-specific" (^99m) Tc was subsequently found to dissociate in vivo. Pre-labelling the macrocycle with (^99m)Tc solved the "non-specifics" problem but required a pH which meant that the conjugation step was too slow for sufficient specific activity to be bound. A phenol-pendent derivative of cyclam was found to incorporate (^99m)Tc at a lower pH than cyclam itself. The "non-specific" binding of copper to the protein was minimised using a low pH labelling strategy in conjunction with a chelate wash. Macrocycle antibody conjugates labelled manner provide very promising biodistribution profiles in normal mice. A labelling buffer was selected to enhance the rate of uptake of copper by the macrocycle at low pH. Macrocycle-antibody conjugates containing 13N(_4), which was found to provide faster association kinetics than cyclam, have been prepared and await radiolabelling studies. A derivative of I3N(_4), containing 4 carboxylic acid donor sites, has been functionalised for conjugation to an antibody to act as a (^90)Y binder.

For the treatment of cancer, Auger-electron emitting radionuclides are strongly dependent on their close proximity to DNA to utilize the local therapeutic potential of the Auger electrons. This thesis investigates a two-step targeting approach that uses targeting liposomes for the delivery of an Auger-electron emitter, 125I, coupled to a DNA-binding compound, Comp1, to the tumour-cell DNA. In the first step the liposome targets overexpressed cell-surface receptors. Receptors belonging to epidermal growth factor receptor (EGFR) family are overexpressed in a number of different cancers and are therefore suitable targets. The second step is transportation of the radionuclide to the cell nucleus utilizing a DNA-binding compound. The DNA-binder used in this thesis is a daunorubicin derivative called Comp1. Papers I and II are in vitro characterizations of the targeting liposomes. Both EGFR- and HER2-targeting liposomes delivered 125I-Comp1 receptor specifically to tumour cells, and were efficient in decreasing growth of cultured tumour cells. Paper II also included a biodistribution of 125I-Comp1 delivered by HER2-targeting liposomes in tumour-bearing mice. The results gave a time-dependent uptake in tumours differed from when non-targeting liposomes encapsulating 125I-Comp1 were given. Paper III investigates the therapeutic effect of 125I-Comp1 delivered by HER2-targeting liposomes, in an animal model that mimics a situation of disseminated tumour cells in the abdomen. 125I-Comp1 delivered by HER2-targeting liposomes effectively prolonged survival of the mice in a dose-dependent relation. Several mice in the groups receiving the highest doses were tumour-free at the end of the study. Paper IV compares different lipid compositions of the liposomes with respect to leakage, cellular uptake and therapeutic efficacy of delivered 125I-Comp1on cultured cells. Liposomes containing sphingomyelin or dihydrosphingomyelin retained drug more efficiently and exhibited more receptor specific delivery properties than distearoylglycerophosphatidylcholine (DSPC) containing liposomes. However, it was the DSPC-containing liposomes that displayed best growth inhibition on cultured tumour cells. The thesis concludes that 125I-Comp1 delivered by targeting liposomes is a promising candidate for effective radionuclide therapy.

At the Gesellschaft für Schwerionenforschung in Darmstadt a therapy unit for heavy ion cancer treatment has been established in collaboration with the Deutsches Krebsforschungszentrum Heidelberg, the Radiologische Universitätsklinik Heidelberg and the Forschungszentrum Rossendorf. For quality assurance the dual-head positron camera BASTEI (Beta Activity meaSurements at the Therapy with Energetic Ions) has been integrated into this facility. It measures ß+-activity distributions generated via nuclear fragmentation reactions within the target volume. BASTEI has about 4 million coincidence channels. The emission data are acquired in a 3D regime and stored in a list mode data format. Typically counting statstics is two to three orders of magnitude lower than those of typical PET-scans in nuclear medicine. Two iterative 3D reconstruction algorithms based on ISRA (Image Space Reconstruction Algorithm) and MLEM (Maximum Likelihood Expectation Maximization), respectively, have been adapted to this imaging geometry. The major advantage of the developed approaches are run-time Monte-Carlo simulations which are used to calculate the transition matrix. The influences of detector sensitivity variations, randoms, activity from outside of the field of view and attenuation are corrected for the individual coincidence channels. Performance studies show, that the implementation based on MLEM is the algorithm of merit. Since 1997 it has been applied sucessfully to patient data. The localization of distal and lateral gradients of the ß+-activity distribution is guaranteed in the longitudinal sections. Out of the longitudinal sections the lateral gradients of the ß+-activity distribution should be interpreted using a priori knowledge.

At the Gesellschaft für Schwerionenforschung in Darmstadt a therapy unit for heavy ion cancer treatment has been established in collaboration with the Deutsches Krebsforschungszentrum Heidelberg, the Radiologische Universitätsklinik Heidelberg and the Forschungszentrum Rossendorf. For quality assurance the dual-head positron camera BASTEI (Beta Activity meaSurements at the Therapy with Energetic Ions) has been integrated into this facility. It measures ß+-activity distributions generated via nuclear fragmentation reactions within the target volume. BASTEI has about 4 million coincidence channels. The emission data are acquired in a 3D regime and stored in a list mode data format. Typically counting statstics is two to three orders of magnitude lower than those of typical PET-scans in nuclear medicine. Two iterative 3D reconstruction algorithms based on ISRA (Image Space Reconstruction Algorithm) and MLEM (Maximum Likelihood Expectation Maximization), respectively, have been adapted to this imaging geometry. The major advantage of the developed approaches are run-time Monte-Carlo simulations which are used to calculate the transition matrix. The influences of detector sensitivity variations, randoms, activity from outside of the field of view and attenuation are corrected for the individual coincidence channels. Performance studies show, that the implementation based on MLEM is the algorithm of merit. Since 1997 it has been applied sucessfully to patient data. The localization of distal and lateral gradients of the ß+-activity distribution is guaranteed in the longitudinal sections. Out of the longitudinal sections the lateral gradients of the ß+-activity distribution should be interpreted using a priori knowledge.

No / Various saponins, plant glycosides with favorable anti-tumorigenic properties, have been used to inhibit tumor cell growth by cell cycle arrest and apoptosis with IC50 values of up to 0.2 μM. We describe several groups of saponins (dioscins, saikosaponins, julibrosides, soy saponins, ginseng saponins and avicins) currently investigated for their use in tumor therapy. We focus on cellular and systemic mechanisms of tumor cell growth inhibition both in vitro and in vivo, combinational approaches with saponins and conventional tumor treatment strategies, and successful syntheses of saponins. The increasing interest in saponins for tumor therapy is very promising for the future development of sophisticated anti-cancer drugs.

L'apparition d’un développement cancérigène est souvent caractéristique des tumeurs de la région de la tête et du cou. En raison des altérations prémalignes et malignes fréquentes, il n'est souvent pas possible de supprimer complètement la tumeur par chirurgie.Il en résulte un risque élevé de récidive tumorale. Par conséquent, cette recherche de doctorat vise à développer des nanoparticules photocatalytiques (NPs) qui seront utilisées localement en complément de la thérapie tumorale traditionnelle. Ces NPs, une fois absorbées par les cellules tumorales induiront la mort des cellules photocatalytiques par activation de lumière UV. Des NPs de TiO2 ayant des propriétés photocatalytiques et une taille moyenne inférieure à 20 nm étaient donc synthétisées. La biocompatibilité des NPs, leur absorption dans les cellules et un ciblage tumoral efficace devraient être garantis par une modification de surface des particules avec des molécules organiques dendritiques permettant un contrôle précis de la charge de surface des particules ainsi que la possibilité de couplage avec des anticorps. Un autre objectif était la combinaison de propriétés thérapeutiques et diagnostiques dans le système de NPs par exemple réalisé par incorporation d'agent luminescent. Cette recherche était menée à l'Université de Bordeaux (synthèse des molécules organiques pour la fonctionnalisation des particules) en coopération avec l'Institut Fraunhofer de recherche en silicate ISC à Würzburg, Allemagne (synthèse des nanoparticules). / The occurrence of field cancerization is characteristic for tumours of the head and neck region. Due to these widespread premalignant and malignant alterations, it is frequently not possible to entirely remove the tumour by surgery. This results in a high risk of tumour recurrence. Therefore, this PhD research aimed to develop photocatalytic nanoparticles (NPs) as completion of the traditional tumour therapy. These NPs are supposed to be incorporated by tumour cells and to induce photocatalytic cell death by UV light activation. TiO2 with convincing photocatalytic properties and an average size smaller than 20 nm should therefore be synthesized. NP biocompatibility, their uptake into cells and an efficient tumour targeting should be guaranteed by surface modification of the particles with dendritic organic molecules that allow a precise control of the surface charge of the particles as well as antibody coupling.A further objective was the combination of therapeutic and diagnostic properties within the NPsystem realized for example via introduction of a luminescent dye. This research was carried out at the University of Bordeaux (synthesis of organic molecules for particle functionalization) in cooperation with the Fraunhofer Institute for Silicate Research ISC in Würzburg, Germany (nanoparticle synthesis).